<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04962360</url>
  </required_header>
  <id_info>
    <org_study_id>rmc26021ctil</org_study_id>
    <nct_id>NCT04962360</nct_id>
  </id_info>
  <brief_title>The Effect of Nutritional Formula Supplementation on Linear Growth of Growth Hormone (GH) Treated Prepubertal Children With Idiopathic Short Stature (ISS) After 2 Years From the Beginning of GH-therapy</brief_title>
  <official_title>The Effect of Nutritional Formula Supplementation on Linear Growth of GH Treated Prepubertal Children With Idiopathic Short Stature (ISS) After 2 Years From the Beginning of GH-therapy: a Randomized, Double- Blind, Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rabin Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rabin Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed study is a double blind, randomized, placebo controlled study. The aim of the&#xD;
      study is to evaluate the effect of combined growth hormone (GH) treatment &amp;nutritional&#xD;
      formula supplementation versus GH &amp; placebo on growth parameters in 64 children with&#xD;
      Idiopathic Short Stature (ISS) after the second year of GH treatment.&#xD;
&#xD;
      Participants will be randomly assigned either to the intervention group or the placebo&#xD;
      control group. Randomization for the two study groups will be made in a ratio of 1:1. Both&#xD;
      participants and study team will be blinded to the type of treatment that each patient will&#xD;
      receive during the study. The randomization will be done according to gender.&#xD;
&#xD;
      Participants in the intervention groups will be treated with the study formula and&#xD;
      participants in the control group will be treated with a placebo low caloric formula (powder&#xD;
      added to water). The study will continue for 6 months of intervention versus active placebo,&#xD;
      with additional 6 months (an extension period), in which participants at both groups, the&#xD;
      intervention and the placebo, will be offered to continue their participation in the study&#xD;
      with the active study supplement.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2021</start_date>
  <completion_date type="Anticipated">October 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>height standard deviation score (SDS)</measure>
    <time_frame>at 6 moths</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>weight standard deviation score</measure>
    <time_frame>at 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>BMI SDS</measure>
    <time_frame>at 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lean body mass</measure>
    <time_frame>at 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>muscle mass</measure>
    <time_frame>at 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fat mass</measure>
    <time_frame>at 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fat mass percentage</measure>
    <time_frame>at 6 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>height SDS</measure>
    <time_frame>at 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Weight SDS</measure>
    <time_frame>at 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>BMI SDS</measure>
    <time_frame>at 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Lean body mass</measure>
    <time_frame>at 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>muscle mass</measure>
    <time_frame>at 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>fat mass</measure>
    <time_frame>at 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>fat mass percentage</measure>
    <time_frame>at 12 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>ISS- Idiopathic Short Stature</condition>
  <arm_group>
    <arm_group_label>Nutritional standardized supplementation formula.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Powder added to water, containing about 25% of recommended daily recommended intake (DRI) for calories, high protein (25% of calories) and multivitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Low caloric formula (Powder added to water) without added vitamins and minerals</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Nutritional supplementation standardized formula</intervention_name>
    <description>Powder added to water, containing about 25% of recommended Daily Recommended Intake (DRI) for calories, high protein (25% of calories) and multivitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake</description>
    <arm_group_label>Nutritional standardized supplementation formula.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Low caloric formula (Powder added to water) without added vitamins and minerals</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. GH treatment for at least 24 months due to idiopathic short stature (ISS)&#xD;
&#xD;
          2. Age 5-10 years inclusive.&#xD;
&#xD;
          3. Tanner stage 1 (gonadarche).&#xD;
&#xD;
          4. BMI &lt;85 percentile for age and gender.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. SGA/ IUGR&#xD;
&#xD;
          2. Diagnosis of GH deficiency&#xD;
&#xD;
          3. Any known morbidity: chronic disease dysmorphic syndromes, bone diseases, organic&#xD;
             brain diseases, neurological disease, past or current malignancy, chronic cardial,&#xD;
             renal or pulmonary problems, metabolic disorders.&#xD;
&#xD;
          4. Any known gastrointestinal problem including absorption problems.&#xD;
&#xD;
          5. Any chronic treatment with medication that might affect appetite, weight or growth&#xD;
             (for example SSRI's, steroids).&#xD;
&#xD;
          6. Any eating disorders and/or psychiatric disorder&#xD;
&#xD;
          7. Milk or other food allergies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Moshe Phillip, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Schnieder Children's Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Moshe Phillip, Prof.</last_name>
    <phone>972-3-9253282</phone>
    <email>mosheph@clalit.org.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alonah Hamou, MSc</last_name>
    <phone>972-39253747</phone>
    <email>alonah@clalit.org.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Schneider children's medical center</name>
      <address>
        <city>Petah tikva</city>
        <country>Israel</country>
      </address>
    </facility>
    <contact>
      <last_name>Moshe Phillip, Prof</last_name>
      <phone>972-3-9253778</phone>
      <email>mosheph@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Naama Fish, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Liora Lazar, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sharon Demol, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>July 4, 2021</study_first_submitted>
  <study_first_submitted_qc>July 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 15, 2021</study_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dwarfism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

